SCHEMBL24018502

SCHEMBL24018502

Cc1ccc(N2CC3CCC(C2)N3C2COC2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K12 Q12852 1/20 0.43
PDE10A Q9Y233 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
DHFR P00374 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
OGA O60502 1/20 0.34
GAA P10253 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20469098 0.91 GRIN2D (0.40) MAP3K12PDE10AGRIN2DGRIN3BGRIN1
SCHEMBL21012663 0.91 PDE10A (0.38) MAP3K12PDE10AGRIN2DGRIN3BGRIN1
SCHEMBL20468999 0.91 PDE10A (0.38) MAP3K12PDE10AGRIN2DGRIN3BGRIN1
SCHEMBL21450070 0.87 GRIN2D (0.42) PDE10AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL20468981 0.86 GRM5 (0.39) MAP3K12
SCHEMBL20456800 0.83 MAP3K12 (0.43) MAP3K12DRD3HTR1ADRD2DRD4
SCHEMBL24018500 0.83 MAP3K12 (0.43) MAP3K12DRD3HTR1ADRD2DRD4
SCHEMBL20469202 0.83 MAP3K12 (0.46) MAP3K12DRD3HTR1ADRD2DRD4
SCHEMBL21675879 0.81 MAP3K12 (0.41) MAP3K12GPR119DHFRMEN1KMT2A
SCHEMBL21588382 0.80 PDE10A (0.44) PDE10AGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3909949-A1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS Gilead Sciences, Inc. (US) 2021-11-17 EP disclosed